

COVINGTON & BURLING

GP 1626
[Handwritten Signature]

1201 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004-2401
TEL 202.662.6000
FAX 202.662.6291
WWW.COV.COM

WASHINGTON
NEW YORK
LONDON
BRUSSELS
SAN FRANCISCO

ANDREA G. REISTER
TEL 202.662.5141
FAX 202.778.5141
AREISTER@COV.COM

November 9, 2000

Commissioner for Patents
Washington, D.C. 20231



Re: U.S. Utility Patent Application
Appl. No.: 09/578,908; Filed: May 26, 2000
For: **Microencapsulated 3-Piperidinyl-Substituted
1,2-Benzisoxazoles and 1,2-Benzisothiazoles**
Inventors: Mesens *et al.*
Our Ref: 00166.0051.US05

RECEIVED
APR 16 2001
TECH CENTER 1600/2900

Sir:

Transmitted herewith for appropriate action by the U.S. Patent and Trademark Office (PTO) are the following documents:

1. Form PTO-1083 (in duplicate);
2. Second Preliminary Amendment; and
3. Return receipt postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-0740 referencing docket number 00166.0051.US05. A duplicate copy of this letter is enclosed.

Respectfully submitted,

Andrea G. Reister
Andrea G. Reister (Reg. No. 36,253)

Enclosures

B

COVING BURLING
1201 Pennsylvania Avenue, N.W.
Washington, D.C. 20004-2401
(202) 662-6000

FORM PTO-1083

Attorney Docket No. 00166.0051.US05

In re application of Mesens *et al.*
Appl. No. 09/578,908

TECH CENTER 1600/2900
APR 16 2001
RECEIVED
RECEIVED

NOV 16 2000

TECH CENTER 1600/2900

Filed: May 26, 2000

For: Microencapsulated 3-Piperidinyl-Substituted
1,2-Benzisoxazoles and 1,2-Benzisothiazoles



THE COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

- Small entity status of this application under 37 CFR §§ 1.9 and 1.27 has been established by a statement previously submitted.
- A statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.
- No additional claim fee is required.

The claim fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)		SMALL ENTITY		OTHER THAN A SMALL ENTITY
	Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra		Rate	Addit. Fee	
Total Claims	* 28	MINUS	** 20	=	8		x 9 =	\$ 00.00	
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM									
							x 39 =	\$ 00.00	x 18 = \$ 144.00
							+130 =	\$ 00.00	x 80 = \$ 160.00
							Total Addit. Fee	\$ 00.00	+260 = \$ 00.00
							Or	TOTAL	\$ 304.00

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

- Please charge my Deposit Account No. 50-0740 in the amount of \$304.00 referencing docket number 00166.0051.US05. A duplicate copy of this sheet is attached.
- Check number * in the amount of \$ *.00 is attached.
- The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0740 referencing docket number *. A duplicate copy of this sheet is attached.
- Any filing fees under 37 CFR § 1.16 for the presentation of extra claims.
- Any patent application processing fees under 37 CFR § 1.17.

Date: November 9, 2000

Andrea G. Reister (Reg. No. 36,253) B